Axsome Therapeutics AXSM Payments Of Stock Issuance Costs
Payments Of Stock Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's payments of stock issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's payments of stock issuance costs?
- Axsome Therapeutics (AXSM) reported payments of stock issuance costs of $95K in Q1 2026.
- How has Axsome Therapeutics's payments of stock issuance costs changed year-over-year?
- Axsome Therapeutics's payments of stock issuance costs decreased by 75.8% year-over-year, from $393K to $95K.
- What is the long-term trend for Axsome Therapeutics's payments of stock issuance costs?
- Over 2 years (2021 to 2025), Axsome Therapeutics's payments of stock issuance costs has grown at a 131.7% compound annual growth rate (CAGR), from $223K to $1.2M.
- What does payments of stock issuance costs mean?
- Cash paid for fees related to issuing new shares of stock.
- How do you interpret payments of stock issuance costs?
- High issuance costs relative to proceeds may indicate inefficient capital raising or high market friction.
- How does payments of stock issuance costs compare across companies?
- Standard industry metric; typically a small percentage of total equity raised depending on the size of the offering.